Research
Temporal control of CAR expression by a tumor-targeting albumin adapter and logic gating enhances CAR-T cell therapy for solid tumors
Cell Reports Medicine · By Jin Chen, Lei Zhao, Cui Shen, Yang Zhou, Yangjing Li, Yuzheng Zhu, Mengqian Gao, Xinyue Wang, Yulun Huang & Yiran Zheng ·
The Brief
- Chen et al. describe MANAGE CAR-T cells that use an artificial-antigen-sensing synNotch receptor to gate CAR expression.
- An albumin-based tumor-targeting adapter carrying the artificial antigen is used to prime the CAR-T cells.
- Adjusting the adapter dosing schedule is reported to enable tumor-restricted CAR-T activity in solid tumors.
Why it matters
It describes a logic-gated, time-controlled CAR-T approach aimed at making cell therapy more targeted against solid tumors, a known hurdle for CAR-T treatment.
Who’s affected
- cancer immunotherapy researchers
- CAR-T cell developers
- #car-t
- #cell therapy
- #solid tumors
- #synthetic biology
- #immunotherapy
Chen et al. develop MANAGE CAR-T cells that employ an artificial-antigen-sensing synNotch receptor to gate CAR expression and an albumin-based tumor-targeting adapter bearing the artificial antigen for priming. Adjusting the adapter dosing schedule enables tumor-restricted and…
Timeline
Study published in Cell Reports Medicine
cell.com
Temporal control of CAR expression by a tumor-targeting albumin adapter and logic gating enhances CAR-T cell therapy for solid tumors